Peptide receptor radionuclide therapy for neuroendocrine Tumors in Germany: First results of a multi-institutional cancer registry

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 457-465

  Hörsch, Dieter ^a   Ezziddin, Samer ^b   Haug, Alexander ^c   Gratz, Klaus Friedrich ^d   Dunkelmann, Simone ^e   Krause, Bernd Joachim ^e   Schümichen, Carl ^e   Bengel, Frank M ^d   Knapp, Wolfram H ^d   Bartenstein, Peter ^c   Biersack, Hans Jürgen ^b   Plöckinger, Ursula ^f   Schwartz Fuchs, Sabine ^g   Baum, R P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Chirurgische Klinik Munchen Bogenhausen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; LUTETIUM 177; YTTRIUM 90;

ABLATION THERAPY; ADULT; AGED; APPENDIX CANCER; CANCER RADIOTHERAPY; CANCER REGISTRY; CECUM TUMOR; CHILD; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM TUMOR; REVIEW; SCHOOL CHILD; SMALL INTESTINE TUMOR; STOMACH TUMOR; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 84867093346     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_25     Document Type: Review

References (17)

1. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS et al (2010) 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652-1659
2. de Jong M, Breeman WA, Bernard HF et al (1999) Therapy of neuroendocrine tumours with radiolabeled somatostatin-analogues. Q J Nucl Med 43:356-366 (Pubitemid 30113564)
3. Hörsch D, Prasad V, Petrovitch A, Baum RB (2010) Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptidereceptor radiotherapy is safe and effective: Report of 30 consecutive patients. J Clin Oncol 28(suppl):e14634 (abstr)
4. Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 22:2416-2423
5. Kwekkeboom D, de Herder W, Kam B et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130
6. Kwekkeboom DJ, Kam Bl, van Essen M et al (2010) Somatostatin receptor based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53-R73
7. Merola E, Capurso G, Campana D (2010) Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Dig Liver Dis 42:457-458
8. Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256-265
9. Raymond E, Niccoli P, Raoul J et al (2011) Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol 29(suppl):4008 (abstr)
10. Rollman EJ, Melis M, Valkema R (2010) Kidney protection during peptide receptor radionuclide therapy with somatostatin analoques. Eur J Nucl Mol Imaging 37:1018-1031
11. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228-247 (Pubitemid 43817847)
12. Seregni E, Maccauro M, Coliva A et al (2010) Treatment with tandem [(90)Y] DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: Preliminary results. Q J Nucl Med Mol Imaging 54(1):84-91
13. Strosberg J, Cheema A, Weber J et al (2011) Prognostic validity of a novel American joint committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044-3049
14. Valkema R, Pauwels S, Kvols LK et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147-156 (Pubitemid 43320450)
15. Wehrmann C, Senftleben S, Zachert C (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22:406-416 (Pubitemid 47067899)
16. Yao JC, Hassan M, Phan A et al (2008) One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
17. Zaknun JJ et al. (eds) Practical guidance on peptide receptor radionuclide therapy (PRRNT) for neuroendocrine tumors. (in press IAEA)